Publication Date
| In 2026 | 0 |
| Since 2025 | 0 |
| Since 2022 (last 5 years) | 0 |
| Since 2017 (last 10 years) | 1 |
| Since 2007 (last 20 years) | 1 |
Descriptor
| Adolescents | 1 |
| Age Differences | 1 |
| Attention Deficit… | 1 |
| Autism | 1 |
| Behavior Modification | 1 |
| Behavior Problems | 1 |
| Children | 1 |
| Comorbidity | 1 |
| Drug Therapy | 1 |
| Foreign Countries | 1 |
| Gender Differences | 1 |
| More ▼ | |
Source
| Journal of Intellectual… | 1 |
Author
| Dinnissen, Mariken | 1 |
| Hoekstra, Pieter J. | 1 |
| Popma, Arne | 1 |
| Reijnen, Sam | 1 |
| Reurts, Eva Enneke | 1 |
| Troost, Pieter W. | 1 |
Publication Type
| Journal Articles | 1 |
| Reports - Research | 1 |
Education Level
Audience
Location
| Netherlands | 1 |
Laws, Policies, & Programs
Assessments and Surveys
| Wechsler Intelligence Scale… | 1 |
What Works Clearinghouse Rating
Peer reviewed
Direct linkReurts, Eva Enneke; Troost, Pieter W.; Dinnissen, Mariken; Reijnen, Sam; Hoekstra, Pieter J.; Popma, Arne – Journal of Intellectual Disabilities, 2021
A retrospective chart study of patients on open-label aripiprazole treatment was conducted in the Netherlands to add to the knowledge of aripiprazole in children and young adults with mild and borderline intellectual disabilities (IDs). Fifty-three youths, mean age 14.7 ± 3.4 years and mean IQ 64.5 ±13.8, were included. Treatment responders were…
Descriptors: Mild Intellectual Disability, Drug Therapy, Outcomes of Treatment, Foreign Countries
